Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3164 results found
Expand All
Apply All
3164 results found

GHG Benefits of the Consumer and Fuel Retailer Choice Act
Share
Letters, Testimony & Comments  •  June 7, 2017
BIO IES: GHG Benefits of the Consumer and Fuel Retailer Choice Act Over the next 10 years, summer use of E15 can save between 7 million and 10.4 million metric tons of CO2 equivalent GHG emissions. The savings are equal to taking 1.4 million to 2.2 million cars off the road over the 10-year period. If this legislation encourages more U.S. fuel retailers to offer consumers higher ethanol blends, the greenhouse gas emission savings will increase.
Read More

Convention to Feature Modern Ag Innovation Programming
Share
Press Release  •  June 6, 2017
Washington, D.C. (June 6, 2017) – Today, BIO announced programming and speakers for its Modern Ag Innovation Day, which will take place on Tuesday, June 20th at BIO’s 2017 International Convention (June 19-22 in San Diego). Programming will feature agricultural, business, and civic leaders from around the world discussing the contributions biology-based innovations have made to agriculture.
Read More

GM Crops Increase Environmental Sustainability and Farmer Incomes
Share
Press Release  •  June 5, 2017
Washington, D.C. (June 5, 2017) – Over the last twenty years, biotech crops have increased agriculture’s environmental sustainability, while providing significant economic benefits, according to a newly released global impacts study.
Read More

BIO Statement on Supreme Court Ruling in Impression Products v. Lexmark International
Share
Press Release  •  May 30, 2017
Washington, DC (May 30, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to the Supreme Court’s ruling in Impression Products  v. Lexmark International.
Read More

BIO submits comments to USDA’s Animal and Plant Health Inspection Service RE: Availability of an Environmental Assessment for the Field Release of Genetically Engineered Diamondback Moths
Share
Letters, Testimony & Comments  •  May 25, 2017
May 19, 2017Docket No. APHIS-2014-0056Regulatory Analysis and DevelopmentPlant Protection Division - APHISStation 3A–03.84700 River Road Unit 118Riverdale, MD 20737–1238.http://www.regulations.gov/#!docketDetail;D=APHIS-2014-0056Re: Animal and Plant Health Inspection Service Docket No. APHIS–2014–0056; Availability of an Environmental Assessment for the Field Release of Genetically Engineered Diamondback MothsTo Whom It May Concern:The Biotechnology Innovation Organization (BIO) appreciates this opportunity to provide comments to the United States Department of Agriculture (USDA) Animal Plant Health Inspection Service (APHIS). BIO is the world's largest biotechnology trade association, representing small and large companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO represents its members in a number of matters related to agricultural biotechnology, and in particular, has a strong interest in the sound regulation of animal biotechnology. These comments by BIO address the environmental assessment for the field release of genetically engineered diamondback moths and further support BIO’s advocacy for the sound regulation of animal biotechnology.APHIS prepared this environmental assessment (EA) in response to Cornell University’s application for a permit1 to conduct an experimental release of the genetically engineered (GE) diamondback moth (Plutella xylostella) strain OX4319L-Pxy. Pursuant to the National Environmental Policy Act of 1969 (NEPA), APHIS thoroughly assessed the potential impacts of its decision to grant or deny a permit on key resource areas: human health, the physical and biotic environments, including threatened and endangered species. BIO concurs with the factual accuracy, scientific validity and thoroughness of…
Read More

POET Founder, Chairman and CEO Jeff Broin to Receive 2017 BIO George Washington Carver Award
Share
Press Release  •  May 25, 2017
BIO today announced that POET Founder, Chairman and CEO Jeff Broin will receive the 10th annual George Washington Carver Award for Innovation in Industrial Biotechnology. The award will be presented on Monday July 24, 2017, during a morning plenary session of the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.
Read More

BIO Applauds Creation of FDA Opioid Policy Steering Committee
Share
Press Release  •  May 24, 2017
Washington, DC (May 24, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the announced creation of an Opioid Policy Steering Committee at the Food and Drug Administration (FDA):
Read More

Astellas Expands Advocacy Engagement with Focused Outreach
Share
Press Release  •  May 23, 2017
Astellas recognizes the crucial role that patient groups play in enhancing and extending the lives of patients. Sponsoring events such as the BIO Patient and Health Advocacy Summit to be held on November 3-4 is a way the Astellas Stakeholder Engagement team is supporting that goal. Astellas’ Stakeholder Engagement team is focused on collaborating with patient advocacy groups with the aim to: build and strengthen relationships with stakeholders and influential thought leaders elevate the patient voice within Astellas to ensure patient-centric decision making, and galvanize collective action among stakeholders to improve patient outcomes, address access challenges, and develop resources for unmet needs.This approach is in line with the Astellas Way, a set of values that Astellas employees share, which focuses on patients first, ownership, results, openness and integrity.By supporting patient advocacy groups and organizations that advocate for improved patient care, Astellas works to strengthen the power patients have to influence positive changes in healthcare. In all of the support and funding Astellas provides, we work diligently to maintain the highest levels of transparency and integrity.Our Stakeholder Engagement team has developed several programs to help facilitate dialogue about the patient journey and connect advocates across various therapeutic areas: The Patient Advocates Advisory Committee serves as a confidential sounding board for seeking and evaluating patient feedback regarding healthcare needs and services, strengthening Astellas’ ability to meet the needs of patients. Astellas’ annual Patient Advocacy Summit gathers more than 100 of the most influential names in patient advocacy, healthcare and Astellas leaders to discuss the most prevalent issues related to medical innovation and patient access to quality care in the US and Canada. Changing Tomorrow Together, an interactive website, stimulates dialogue and creates opportunities…
Read More

BIO Statement on President’s Proposed 2018 Budget
Share
Press Release  •  May 23, 2017
Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Trump’s FY 2018 budget proposal.
Read More

Biotech Industry Continues Strong Growth in 2016; San Diego Setting Pace for State, Nation
Share
Press Release  •  May 17, 2017
Mayor Faulconer, Industry Leaders Reveal Latest Data, Including Major Economic Benefits of June BIO 2017 Convention
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 288
  • 289
  • 290
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO